Drug Trial Radar · NCT00639158
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Last checked: Nov 20, 2026Latest source record: Jun 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
543
Actual
Start
Feb 2008
Primary completion
Oct 2008
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
Conditions
- Dyslipidemias
- Coronary Heart Disease
- Combined (Atherogenic) Dyslipidemia
- Mixed Dyslipidemia
Interventions
ABT-335Drug
135 mg capsule, daily, 12 weeks
placeboDrug
placebo capsule, daily, 12 weeks
atorvastatinDrug
40 mg, tablet, daily, 12 weeks
ezetimibeDrug
10 mg capsule, daily, 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Percent Change in Triglycerides From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
- Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final VisitTime frame: Baseline to 12 weeks (Final Visit)
Locations
118 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Columbiana, Alabama
Site not named
Hueytown, Alabama
Site not named
Ozark, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Sierra Vista, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Carmichael, California
Site not named
Concord, California
Site not named
Long Beach, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Norwalk, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
Santa Ana, California
Site not named
Tustin, California
Site not named
West Hills, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Clearwater, Florida
Site not named
Delray Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Holly Hill, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Kissimmee, Florida
Site not named
Longwood, Florida
Site not named
Miami, Florida
Site not named
New Port Richey, Florida
Site not named
New Smyrna Beach, Florida
Site not named
Ocala, Florida
Site not named
Ormond Beach, Florida
Site not named
Pembroke Pines, Florida
Site not named
Sarasota, Florida
Site not named
Tampa, Florida
Site not named
Winter Haven, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Roswell, Georgia
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.